Treatment of depressive symptoms in patients with heart failure

The comparison of the efficacy of Agomelatine and Sertraline in treatment of depression symptoms in patients with heart failure in double-blind randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170606034348N7

Enrollment

Registered

2022-12-26

Start date

2023-01-20

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression. Major depressive disorder, single episode, mild

Interventions

Intervention 1: Intervention group 1: Sertraline group patients (Soban company) will receive one 50 mg tablet daily (depending on the patient's response, it is possible to increase the dose up to a ma

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age over 18 years old With heart failure Depressive Disorder (Based on the questionnaire) Willingness to participate in the study

Exclusion criteria

Exclusion criteria: Patient with cognitive impairment Mental retardation History of substance use Bipolar disorder Kidney/Liver failure Any uncontrolled medical illness

Design outcomes

Primary

Measure	Time frame
Patient´s depressive condition. Timepoint: Before intervention (first visit) ,the end of the fourth week (second visit), the end of the eighth week (third visit), the end of the twelfth week (the fourth visit). Method of measurement: BDI and Hamilton Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Angela Hamidia

Babol University of Medical Sciences

angela_7633@yahoo.com+98 11 3229 1951

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026